Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
66.3 USD | +0.22% | -3.63% | -18.33% |
02:56pm | BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89 | MT |
02:15pm | Leerink Partners Adjusts Gilead Sciences Price Target to $74 From $79 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.33% | 82.5B | |
+27.97% | 672B | |
+23.68% | 550B | |
-7.02% | 351B | |
+14.85% | 317B | |
+6.25% | 292B | |
+2.13% | 211B | |
-0.31% | 203B | |
-11.81% | 144B | |
-8.80% | 141B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences : Trodelvy Product Now Recommended As Triple-Negative Breast Cancer Treatment Under NCCN Guidelines